IL146206A0 - Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration - Google Patents

Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration

Info

Publication number
IL146206A0
IL146206A0 IL14620600A IL14620600A IL146206A0 IL 146206 A0 IL146206 A0 IL 146206A0 IL 14620600 A IL14620600 A IL 14620600A IL 14620600 A IL14620600 A IL 14620600A IL 146206 A0 IL146206 A0 IL 146206A0
Authority
IL
Israel
Prior art keywords
pharmacokinetic
pharmacodynamic modeling
erythropoietin administration
erythropoietin
administration
Prior art date
Application number
IL14620600A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22458537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146206(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL146206A0 publication Critical patent/IL146206A0/xx

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Primary Health Care (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
IL14620600A 1999-05-11 2000-05-10 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration IL146206A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13341899P 1999-05-11 1999-05-11
PCT/US2000/012629 WO2000067776A1 (en) 1999-05-11 2000-05-10 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration

Publications (1)

Publication Number Publication Date
IL146206A0 true IL146206A0 (en) 2002-07-25

Family

ID=22458537

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14620600A IL146206A0 (en) 1999-05-11 2000-05-10 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration

Country Status (16)

Country Link
US (5) US6747002B2 (pl)
EP (1) EP1176975A4 (pl)
JP (2) JP2003523940A (pl)
KR (1) KR20020008186A (pl)
CN (2) CN1572320A (pl)
AU (2) AU4709400A (pl)
BR (1) BR0010316A (pl)
CA (1) CA2372782A1 (pl)
HU (1) HUP0300333A3 (pl)
IL (1) IL146206A0 (pl)
MX (1) MXPA01011429A (pl)
NO (1) NO20015323L (pl)
PL (1) PL360581A1 (pl)
RU (1) RU2248215C2 (pl)
WO (2) WO2000067776A1 (pl)
ZA (1) ZA200109527B (pl)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
AU2001261723B2 (en) 2000-05-18 2007-10-25 Aesynt Incorporated Distributed remote asset and medication management drug delivery system
US7860583B2 (en) 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
US9741001B2 (en) 2000-05-18 2017-08-22 Carefusion 303, Inc. Predictive medication safety
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
US10062457B2 (en) 2012-07-26 2018-08-28 Carefusion 303, Inc. Predictive notifications for adverse patient events
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
BR0214217A (pt) * 2001-11-16 2004-09-21 Childrens Medical Center Aumento de função de órgão
JP2005530678A (ja) * 2001-11-28 2005-10-13 オーソーマクニール ファーマシューティカル， インコーポレイテッド 貧血治療用のエリスロポエチン投与療法
AU2002351177A1 (en) 2001-11-29 2003-06-10 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
CN102552263A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2004238392A (ja) * 2003-01-14 2004-08-26 Nipro Corp 安定化された蛋白質性製剤
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
DE102004010516A1 (de) * 2004-03-04 2005-09-22 Bayer Technology Services Gmbh Verbessertes Verfahren zur zeitlichen Dosierung von Arzneistoffen
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
KR20070015549A (ko) * 2004-03-26 2007-02-05 얀센 파마슈티카 엔.브이. 에리트로포이에틴의 병용 용량요법
EP2386640B1 (en) 2004-08-26 2015-01-28 EnGeneIC Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
DK2990073T3 (en) 2004-11-24 2018-08-13 Bayer Healthcare Llc DEVICES AND SYSTEMS FOR DELIVERING FLUIDS
KR101931899B1 (ko) 2005-05-09 2018-12-21 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CN102743382B (zh) * 2005-09-19 2016-12-07 诺伊罗纳森特公司 刺激神经形成和抑制神经元变性的方法和组合物
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
CN101046831B (zh) * 2006-03-31 2010-09-08 上海中医药大学 中药多组分药动-药效结合数学模型的构建和计算方法
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US9878043B2 (en) 2006-06-23 2018-01-30 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US8012744B2 (en) 2006-10-13 2011-09-06 Theranos, Inc. Reducing optical interference in a fluidic device
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
US9302044B2 (en) 2006-12-29 2016-04-05 Bayer Healthcare Llc Patient-based parameter generation systems for medical injection procedures
DK2865755T3 (en) 2007-03-30 2017-05-15 Engeneic Molecular Delivery Pty Ltd BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
EP1992355A1 (en) * 2007-05-16 2008-11-19 Eberhardt Spanuth Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
CN101827933B (zh) * 2007-06-08 2014-01-29 韦克福里斯特大学健康科学院 治疗肾功能衰竭的选择性细胞疗法
US9580688B2 (en) * 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
AU2008265600B2 (en) 2007-06-21 2013-10-31 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
ES2447875T3 (es) 2007-10-02 2014-03-13 Theranos, Inc. Dispositivos modulares para punto de cuidados y usos de los mismos
US20090271164A1 (en) * 2008-01-03 2009-10-29 Peng Joanna Z Predicting long-term efficacy of a compound in the treatment of psoriasis
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
RU2390779C2 (ru) * 2008-07-10 2010-05-27 Федеральное государственное унитарное предприятие "Антидопинговый центр" Способ определения приема эритропоэтина при допинговом контроле спортсменов
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
KR102428795B1 (ko) * 2008-11-12 2022-08-04 인리젠 분리된 신장 세포 및 이의 용도
CA3081708C (en) 2009-10-19 2023-10-03 Theranos Ip Company, Llc Integrated health data capture and analysis system
HRP20210334T1 (hr) 2009-12-11 2021-04-02 Medregen, Llc Metode liječenja u kojima se primjenjuju mobilizatori matičnih stanica i imunosupresivna sredstva
AU2011203456B2 (en) 2010-01-04 2014-07-31 Mayo Foundation For Medical Education And Research Erythropoietic Stimulating Agent (ESA) dosage determination
WO2011119738A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Methods of treatment using stem cell mobilizers
TWI576091B (zh) * 2010-03-23 2017-04-01 費森尼斯醫療德國公司 造血作用刺激劑（ｅｓａ）效果之預測方法與裝置及其投予劑量之決定方法與裝置
WO2011163506A2 (en) 2010-06-23 2011-12-29 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent
WO2011163578A2 (en) * 2010-06-24 2011-12-29 Medrad, Inc. Modeling of pharmaceutical propagation and parameter generation for injection protocols
CA3065694A1 (en) 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
EP4024029A3 (en) 2011-01-21 2022-09-14 Labrador Diagnostics LLC Systems and methods for sample use maximization
WO2012166795A1 (en) * 2011-05-30 2012-12-06 String Therapeutics Inc. Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling
US9852267B2 (en) * 2011-09-30 2017-12-26 University Of Louisville Research Foundation, Inc. System and method for personalized dosing of pharmacologic agents
CN102663218B (zh) * 2011-10-28 2017-12-19 天津大学 氟喹诺酮类抗菌药基于理化性质的药时曲线预测模型
US9949704B2 (en) 2012-05-14 2018-04-24 Bayer Healthcare Llc Systems and methods for determination of pharmaceutical fluid injection protocols based on x-ray tube voltage
WO2014043295A1 (en) 2012-09-14 2014-03-20 University Of Massachusetts Methods and devices for determining optimal agent dosages
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
WO2014190200A1 (en) 2013-05-22 2014-11-27 Carefusion 303, Inc. Medication workflow management
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US10430554B2 (en) 2013-05-23 2019-10-01 Carefusion 303, Inc. Medication preparation queue
JP6660288B2 (ja) 2013-03-13 2020-03-11 ケアフュージョン ３０３、インコーポレイテッド 患者固有投薬管理システム
EP4195119A1 (en) 2013-03-13 2023-06-14 Carefusion 303 Inc. Predictive medication safety
EP2989569B1 (en) * 2013-04-24 2021-06-23 Fresenius Kabi Deutschland GmbH Method of operating a control device for controlling an infusion device
DK3030232T3 (da) 2013-04-29 2022-10-10 Medregen Llc Sårheling via autolog stamecellemobilisering
JP6190632B2 (ja) * 2013-06-13 2017-08-30 有限会社ネクスティア 赤血球造血刺激因子製剤の投与量決定装置
WO2015006033A1 (en) * 2013-06-20 2015-01-15 Baxter International Inc. Providing a pharmacokinetic drug dosing regime
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法
SG11201602429QA (en) 2013-10-04 2016-04-28 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
DK3054936T5 (da) 2013-10-10 2024-03-18 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
CN106999444B (zh) 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017120225A1 (en) 2016-01-04 2017-07-13 The Johns Hopkins University Use of low dose emetine for inhibition of human cytomegalovirus (hcmv)
KR102415992B1 (ko) 2016-04-15 2022-07-04 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법을 제공하는 방법 및 장치
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
AU2017339841B2 (en) 2016-10-06 2024-11-14 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
CN106682396A (zh) * 2016-12-09 2017-05-17 贵州医科大学 中药组方中四种代表成分的pk‑pd结合模型的建立方法
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
JP6864834B2 (ja) * 2017-06-14 2021-04-28 ニプロ株式会社 投与量決定プログラムおよび投与量決定装置
JP2021532106A (ja) 2018-07-23 2021-11-25 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
CN108776747B (zh) * 2018-08-15 2022-02-01 余鹏 齐多夫定的药效估算方法
EP3870050A2 (en) 2018-10-26 2021-09-01 Abbott Diabetes Care Inc. Methods, devices, and systems for physiological parameter analysis
CN113507936A (zh) 2019-01-04 2021-10-15 安吉尼科分子传输公司 用于治疗赘生性疾病的包封的糖脂抗原
US20220251108A1 (en) 2019-01-23 2022-08-11 The Johns Hopkins University Non-immunosuppressive fk506 analogs and use thereof
CN110487945B (zh) * 2019-08-20 2021-06-04 中山大学 一种针对药物多峰现象的犬药代动力学模型的创建方法
US12357687B2 (en) 2020-03-24 2025-07-15 Engeneic Molecular Delivery Pty Ltd Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
US12551550B2 (en) 2021-07-22 2026-02-17 Engeneic Molecular Delivery Pty Ltd Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same
US20250019702A1 (en) 2021-11-10 2025-01-16 University Of Rochester Gata4-targeted therapeutics for treatment of cardiac hypertrophy
US20250066790A1 (en) 2021-11-10 2025-02-27 University Of Rochester Antisense oligonucleotides for modifying protein expression
EP4581143A1 (en) 2022-08-29 2025-07-09 University of Rochester Antisense oligonucleotide-based anti-fibrotic therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US4748600A (en) 1986-08-22 1988-05-31 Aprex Corporation Interactive drug dispenser
NO881507D0 (no) * 1987-04-10 1988-04-07 Ortho Pharma Corp Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.
JP2632014B2 (ja) 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5416907A (en) * 1990-06-15 1995-05-16 Digital Equipment Corporation Method and apparatus for transferring data processing data transfer sizes
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
RU2152206C1 (ru) * 1997-05-22 2000-07-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Таблетированная форма рекомбинантного человеческого эритропоэтина для перорального применения и способ ее получения
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US6067524A (en) * 1999-01-07 2000-05-23 Catalina Marketing International, Inc. Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data

Also Published As

Publication number Publication date
US6747002B2 (en) 2004-06-08
HUP0300333A2 (hu) 2003-06-28
RU2248215C2 (ru) 2005-03-20
BR0010316A (pt) 2004-04-27
CN1367701A (zh) 2002-09-04
AU4709400A (en) 2000-11-21
US20030198691A1 (en) 2003-10-23
KR20020008186A (ko) 2002-01-29
MXPA01011429A (es) 2003-09-10
ZA200109527B (en) 2003-10-20
CA2372782A1 (en) 2000-11-16
WO2000067776A9 (en) 2003-09-04
US20060128624A1 (en) 2006-06-15
JP2005247858A (ja) 2005-09-15
US20060100150A1 (en) 2006-05-11
US20040157778A1 (en) 2004-08-12
EP1176975A4 (en) 2004-12-01
US20040176297A1 (en) 2004-09-09
WO2000067769A1 (en) 2000-11-16
NO20015323L (no) 2002-01-11
WO2000067769A8 (en) 2001-02-08
AU4838600A (en) 2000-11-21
JP2003523940A (ja) 2003-08-12
HUP0300333A3 (en) 2009-01-28
CN1572320A (zh) 2005-02-02
PL360581A1 (pl) 2004-09-06
WO2000067776A1 (en) 2000-11-16
EP1176975A1 (en) 2002-02-06
NO20015323D0 (no) 2001-10-31

Similar Documents

Publication Publication Date Title
IL146206A0 (en) Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
AU9646198A (en) Isoquinoline derivative and drug
LU90859B1 (en) Pharmaceutical formulations and methods comprising intranasal morphine
IL145947A0 (en) Mutual prodrugs of amlodipine and atrovastatin
AU138764S (en) A set of post hinges
TW435837U (en) Structure improvement of connector
TW417886U (en) Improved structure of connector
LT2001034A (en) Antiarrythmic drug
AU2723400A (en) Attribute-oriented modeling and diagramming technique for software design
AU3905400A (en) Mine support crib and method
GB2342664B (en) Computer booth
TW378680U (en) New model of connector for beam and post
TW399835U (en) Improved case structure of horizontal type computer
TW426180U (en) Improved structure of computer case
TW384789U (en) Improvement of pen stand
AU139343S (en) Post hinge
TW447815U (en) Speaker assembling structure of computer
CA86734S (en) Touch screen dispaly terminal
TW392770U (en) Improved structure of hinge
AU143423S (en) A set of connectors
TW403256U (en) Improved computer connector structure
PL332395A1 (en) Gravitational and displacement apparatus
TW405673U (en) Improved construction of connector
TW414404U (en) Structure improvement of connector
TW395608U (en) Improvement of structure of zero inserting force connector